CCM
CYTK icon

CAAS Capital Management’s Cytokinetics CYTK Stock Holding History

CAAS Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-671,382
Closed -$15.6M – 1088
2021
Q1 		$15.6M Buy
+671,382
New +$14.3M 0.17% 147

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAAS Capital Management's CYTK Position: Q2 2021 in Review

CAAS Capital Management sold out of Cytokinetics (CYTK) in Q2 2021, closing a stake of 671,382 shares — an estimated $15.6M sold.

CAAS Capital Management first reported a position in CYTK in Q1 2021 and held it in 1 quarter. The position peaked at $15.6M in Q1 2021. 190 funds tracked by Wall St. Rank hold CYTK as of Q2 2021.

  • CAAS Capital Management reported no remaining Cytokinetics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 671,382 Cytokinetics shares in Q2 2021, an estimated $15.6M.
  • CAAS Capital Management first reported a position in Cytokinetics in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Cytokinetics position peaked at $15.6M in Q1 2021.
  • 190 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.